Studies investigating mepolizumab in allergic bronchopulmonary aspergillosis (ABPA) treatment in patients with cystic fibrosis (CF)
| Author [ref.] | Type of study | Patients n | Sex (M:F) | Age (years) | CF (yes/no) | ABPA (yes/no) | Reason for mepolizumab administration | Objectives | Mepolizumab dosage | Treatment duration | Follow-up | Results | Benefit (yes/no) |
| Zhang [39] | Case series | 3 | 0:3 | 24–63 | Yes | 2 out of 3 | ABPA/ABPM with high AEC and systemic CSS dependence | Effect on: FEV1, total IgE, AEC, systemic CSS use, CF exacerbation rates | 100 mg every 28 days | 9–12 months | No | ↓ oral CSS use = exacerbation rate ↓ total IgE ↓ AEC (2 out of 3) ↑ FEV1 (1 out of 3) | Yes |
| Boyle [40] | Case report | 1 | 0:1 | 43 | Yes | Yes | CSS dependence Side-effects with CSS, antifungal and omalizumab treatment | 100 mg monthly | 20 months | No | Systemic CSS stop No ABPA exacerbations = FEV1 ↓ AEC = total IgE Improved chest radiograph | Yes |
M: male; F: female; ABPM: allergic bronchopulmonary mycosis; AEC: absolute eosinophil count; CSS: corticosteroids; FEV1: forced expiratory volume in 1 s.